Checking In On 4 Outperforming Biotech Stocks

Among today's outperforming drugmakers are Trevena Inc (NASDAQ:TRVN), OvaScience Inc (NASDAQ:OVAS), La Jolla Pharmaceutical Company (NASDAQ:LJPC), and Kite Pharma Inc (NASDAQ:KITE)

Sep 4, 2015 at 2:46 PM
facebook X logo linkedin


Though short sellers continue to pile on biotech stocks, the sector -- along with airlines -- has weathered today's storm fairly well. In fact, among the 30 sectors we track at Schaeffer's, the Market Vectors Biotech ETF (NYSEARCA:BBH) is the top performer, losing less than 1%. Here's a quick look at four drugmakers that have bucked the broad-market trend south this afternoon.

Trevena Inc (NASDAQ:TRVN) has soared nearly 8%, and has advanced 78% year-to-date, thanks to some recent trial-induced momentum. In fact, the stock yesterday hit an all-time high of $11.94, but was last seen at $10.65. The brokerage bunch certainly respects TRVN's technical tenacity -- as well as its potential to trek even higher. All six analysts covering the security have assigned it a "strong buy" rating.

OvaScience Inc (NASDAQ:OVAS) is outperforming today -- up 3.5% at $17.16 -- but is a long-term laggard, shedding over 61% in 2015. Since late July, the shares have been ushered steadily lower by their 10-day moving average, and -- you guessed it -- short sellers have taken notice. A mind-bending 38.8% of OVAS' float is sold short, equal to 13.4 times its average daily trading levels.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) has more than tripled in value during the past 52 weeks, and it's more of the same today -- with the shares up 3.2% at $34.30. Last Monday, the stock reached a record high of $36.60, as well. That hasn't deterred short sellers from pouncing on the outperformer, as close to 21% of its float is sold short -- or nearly eight days' worth of pent-up buying demand, at LJPC's typical volumes. A capitulation among these bears could fuel the equity's fire.

Finally, Kite Pharma Inc (NASDAQ:KITE) -- which has more than doubled year-over-year -- has added 1.7% to trade at $53.07. For the past couple weeks, the shares have hovered in the $50-$55 range, after flirting with $80 in early August. The brokerage crowd seems to be confident KITE can regain its longer-term upward trajectory, though, as 100% of analysts consider the stock a "strong buy."

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI